CO2020012493A2 - Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc) - Google Patents
Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc)Info
- Publication number
- CO2020012493A2 CO2020012493A2 CONC2020/0012493A CO2020012493A CO2020012493A2 CO 2020012493 A2 CO2020012493 A2 CO 2020012493A2 CO 2020012493 A CO2020012493 A CO 2020012493A CO 2020012493 A2 CO2020012493 A2 CO 2020012493A2
- Authority
- CO
- Colombia
- Prior art keywords
- crystalline forms
- sgc
- stimulant
- guanylyl cyclase
- soluble guanylyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862639846P | 2018-03-07 | 2018-03-07 | |
| PCT/US2019/021080 WO2019173551A1 (en) | 2018-03-07 | 2019-03-07 | Crystalline forms of an sgc stimulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020012493A2 true CO2020012493A2 (es) | 2020-10-30 |
Family
ID=65818696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0012493A CO2020012493A2 (es) | 2018-03-07 | 2020-10-06 | Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc) |
Country Status (21)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111836812A (zh) | 2018-03-07 | 2020-10-27 | 塞科里昂医疗股份有限公司 | sGC刺激剂的晶型 |
| US12220414B2 (en) * | 2018-07-11 | 2025-02-11 | Tisento Therapeutics Inc. | Use of sGC stimulators for the treatment of mitochondrial disorders |
| US20230130739A1 (en) * | 2020-03-26 | 2023-04-27 | Cyclerion Therapeutics, Inc. | DEUTERATED sGC STIMULATORS |
| CN118221651A (zh) * | 2022-12-21 | 2024-06-21 | 广东东阳光药业股份有限公司 | 氟取代的吲唑化合物的晶型及其用途 |
| AU2023412228A1 (en) * | 2022-12-21 | 2025-07-03 | Sunshine Lake Pharma Co., Ltd. | Crystal form of fluorine-substituted indazole compound and use thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| DE19830430A1 (de) | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| CZ302691B6 (cs) | 1998-07-08 | 2011-09-07 | Sanofi - Aventis Deutschland GmbH | N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| CN101939053A (zh) | 2007-09-06 | 2011-01-05 | 默沙东公司 | 可溶性的鸟苷酸环化酶活化剂 |
| CA2711134A1 (en) | 2008-01-24 | 2009-07-30 | Merck Sharp & Dohme Corp. | Angiotensin ii receptor antagonists |
| CA2743864A1 (en) | 2008-11-25 | 2010-06-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| CA2753434C (en) | 2009-02-26 | 2014-07-15 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| US9284301B2 (en) | 2010-03-25 | 2016-03-15 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| UA107112C2 (uk) | 2010-05-27 | 2014-11-25 | Мерк Шарп Енд Доме Корп. | Активатори розчинної гуанілатциклази |
| TWI532737B (zh) | 2010-06-30 | 2016-05-11 | 艾諾屋製藥公司 | 可溶性鳥苷酸環化酶（ｓＧＣ）刺激物 |
| WO2012058132A1 (en) | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| JP5878546B2 (ja) | 2010-11-09 | 2016-03-08 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | ｓＧＣ刺激剤 |
| EP2927231B1 (en) | 2012-11-30 | 2017-09-20 | Astellas Pharma Inc. | Imidazopyridine compounds |
| US9776997B2 (en) | 2013-06-04 | 2017-10-03 | Bayer Pharma Aktiengesellschaft | 3-aryl-substituted imidazo[1,2-A]pyridines and their use |
| CN104327107A (zh) * | 2013-10-17 | 2015-02-04 | 广东东阳光药业有限公司 | 一种氟喹诺酮类抗菌药物的制备方法 |
| US9796733B2 (en) | 2014-06-04 | 2017-10-24 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
| US10844064B2 (en) | 2014-09-17 | 2020-11-24 | Cyclerion Therapeutics, Inc. | sGC stimulators |
| EP3227286B1 (de) * | 2014-12-02 | 2018-12-26 | Bayer Pharma Aktiengesellschaft | Substituierte pyrazolo[1,5-a]pyridine und imidazo[1,2-a]pyrazine und ihre verwendung |
| IL264955B (en) | 2016-09-02 | 2022-06-01 | Ironwood Pharmaceuticals Inc | Fused bicyclic sgc stimulators |
| CN111836812A (zh) | 2018-03-07 | 2020-10-27 | 塞科里昂医疗股份有限公司 | sGC刺激剂的晶型 |
-
2019
- 2019-03-07 CN CN201980017657.XA patent/CN111836812A/zh active Pending
- 2019-03-07 MX MX2020009183A patent/MX2020009183A/es unknown
- 2019-03-07 US US16/976,430 patent/US11466015B2/en active Active
- 2019-03-07 MX MX2023004856A patent/MX2023004856A/es unknown
- 2019-03-07 IL IL276853A patent/IL276853B2/en unknown
- 2019-03-07 EA EA202092109A patent/EA202092109A1/ru unknown
- 2019-03-07 AU AU2019231724A patent/AU2019231724B2/en active Active
- 2019-03-07 JP JP2020546378A patent/JP7423539B2/ja active Active
- 2019-03-07 MX MX2023004857A patent/MX2023004857A/es unknown
- 2019-03-07 MX MX2023004855A patent/MX2023004855A/es unknown
- 2019-03-07 BR BR112020018212-5A patent/BR112020018212A2/pt unknown
- 2019-03-07 MA MA054638A patent/MA54638A/fr unknown
- 2019-03-07 EP EP19712427.4A patent/EP3762389B1/en active Active
- 2019-03-07 CR CR20200458A patent/CR20200458A/es unknown
- 2019-03-07 KR KR1020207028170A patent/KR102782810B1/ko active Active
- 2019-03-07 TW TW108107664A patent/TWI823903B/zh active
- 2019-03-07 SG SG11202008641WA patent/SG11202008641WA/en unknown
- 2019-03-07 ES ES19712427T patent/ES2980256T3/es active Active
- 2019-03-07 MX MX2023004858A patent/MX2023004858A/es unknown
- 2019-03-07 WO PCT/US2019/021080 patent/WO2019173551A1/en not_active Ceased
- 2019-03-07 PE PE2020001347A patent/PE20210124A1/es unknown
- 2019-03-07 CA CA3092683A patent/CA3092683A1/en active Pending
-
2020
- 2020-09-03 CL CL2020002284A patent/CL2020002284A1/es unknown
- 2020-09-05 PH PH12020551394A patent/PH12020551394A1/en unknown
- 2020-10-06 CO CONC2020/0012493A patent/CO2020012493A2/es unknown
-
2021
- 2021-02-04 CL CL2021000301A patent/CL2021000301A1/es unknown
- 2021-12-28 CL CL2021003530A patent/CL2021003530A1/es unknown
- 2021-12-28 CL CL2021003531A patent/CL2021003531A1/es unknown
- 2021-12-28 CL CL2021003536A patent/CL2021003536A1/es unknown
-
2022
- 2022-09-28 US US17/954,713 patent/US12122782B2/en active Active
-
2024
- 2024-10-21 US US18/921,161 patent/US20250115611A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002284A1 (es) | Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc) | |
| PY2224252A (es) | 3,4-dihidro-2,7-naftiridin-1,6(2h,7h)-dionas como inhibidores de mek | |
| PE20181802A1 (es) | Derivados de 4-amino-2-(1h-pirazolo[3,4-b]piridin-3-il)-6-oxo-6,7-dihidro-5h-pirrolo[2,3-d]pirimidina y los respectivos (1h-indazol-3-il) derivados como moduladores cgmp para el tratamiento de enfermedades cardiovasculares | |
| CO2021002651A2 (es) | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met | |
| PE20201185A1 (es) | Inhibidores de la oxacina monoacilglicerol lipasa (magl) | |
| MX388140B (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
| ECSP20078226A (es) | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas | |
| PE20120121A1 (es) | Derivados de imidazopirazina como inhibidores de syk | |
| MX376465B (es) | Compuestos de pirazolo[1,5-4]piridina sustituidos como inhibidores de la quinasa ret. | |
| CL2018002920A1 (es) | Nuevos derivados de pirazolopirimidina | |
| MX370000B (es) | Novedosas n-acil-(3-sustituidas)-(8-sustituidas)-5,6-dihidro-[1,2, 4]triazolo[4,3-a]piracinas como antagonistas selectivos del receptor de nk-3, composición farmacéutica y métodos para su uso en trastornos mediados por el receptor de nk-3. | |
| MX2020008237A (es) | Inhibidores de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol de cgas para tratar enfermedades autoinflamatorias. | |
| ES2721018T3 (es) | N-Acil-(3-sustituido)-(8-metil)-5,6-dihidro-[1,2,4]triazolo[4,3-a]pirazinas como antagonistas selectivos del receptor NK-3, composición farmacéutica, métodos para su uso en trastornos mediados por el receptor de NK-3 | |
| SG10201907576SA (en) | Salts of pi3k inhibitor and processes for their preparation | |
| CL2017001380A1 (es) | 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa | |
| SG10201809189UA (en) | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use | |
| MX2022014858A (es) | Formas solidas de pralsetinib. | |
| UY30706A1 (es) | Diaril, dipiridinil y arilpiridinil derivados y usos de los mismos | |
| UY28524A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina | |
| EP4606433A8 (en) | FORMULATIONS CONTAINING HETEROCYCLIC PROTEIN KINASE INHIBITORS | |
| JOP20170125A1 (ar) | مركبات [8- (فنيل سلفونيل)-3، 8-ديازا ثنائي سيكلو [3. 2. 1] أوكتـ-3-يل] (1h-1، 2، 3-تريازول-4-يل) ميثانون | |
| CR20220661A (es) | NUEVOS DERIVADOS DE [1,2,3]TRIAZOLO[4,5-D]PIRIMIDINA (Divisional 2018-0615) | |
| PA8592801A1 (es) | Derivados biciclicos para el tratamiento del crecimiento celular anormal | |
| CL2013000434A1 (es) | Compuestos derivados de 6,7-dihidro-3h-oxazolo(3,4) pirazina-5,8-diona, composicion farmaceutica que los comprende; proceso para prepararlos, y uso en el tratamiento de patologias mediadas por inhibicion de la emzima pde-5, como disfuncion erectil, litiasis, hiperplasia prostatica, disfuncion sexual femenia. | |
| MX2022005639A (es) | Compuestos inhibidores de pde-5 y/o pde-6 donadores de oxido de nitrogeno. |